Coco Danilo, Leanza Silvana, Boccoli Gianfranco
Department of General Surgery and Surgical Pathology, I.N.R.C.A. (Italian National Institute for Research and Care of Aging), Via della Montagnola 81, 60127 Ancona, Italy.
Department of General Surgery and Surgical Pathology, I.N.R.C.A. (Italian National Institute for Research and Care of Aging), Via della Montagnola 81, 60127 Ancona, Italy.
Int J Surg Case Rep. 2014;5(12):939-43. doi: 10.1016/j.ijscr.2014.07.011. Epub 2014 Oct 16.
Adenocarcinoma of the small intestine is a rare malignancy (the annual incidence in the USA is approximately 3.9 cases per million persons with median age between 60 and 70 years) with limited data available to guide therapeutic decisions. Nonspecific signs and symptoms associated with difficulty in performing small bowel examination is the cause of delayed diagnosis made between 6 and 9 months after appearance of symptoms with the majority of patients presenting with late stage disease and either lymph node involvement or distant metastatic disease.
An 87-year-old man treated 3 years previously for colonic adenocarcinoma with left colectomy, was brought to our attention with a 4.5cm×3.5cm mass in the proximal jejunum associated with another abdominal wall enhancing mass of 5cm in diameter in the rectus muscle. Diagnosis on gross examination after surgical resection was adenocarcinoma stage III (T4N1M0) with involvement of lymph nodes.
According to an analysis of the Surveillance, Epidemiology and End Results (SEER) database, patients who develop either a small or large intestine adenocarcinoma are at increased risk for a second cancer at both intestinal sites. The role of adjuvant therapy in patients who undergo curative resection is unclear. Recent retrospective and prospective studies have helped to clarify the optimal chemotherapy approach for advanced small bowel adenocarcinoma.
With our work, we present our personal case of metachronous primary carcinoma of small bowel following resected colorectal carcinoma and review the literature.
小肠腺癌是一种罕见的恶性肿瘤(美国年发病率约为每百万人3.9例,中位年龄在60至70岁之间),可用于指导治疗决策的数据有限。与小肠检查困难相关的非特异性体征和症状导致症状出现后6至9个月才做出延迟诊断,大多数患者就诊时已处于疾病晚期,伴有淋巴结受累或远处转移性疾病。
一名87岁男性,3年前因结肠腺癌接受左半结肠切除术,现因空肠近端有一个4.5cm×3.5cm的肿块以及腹直肌处另一个直径5cm的腹壁强化肿块而引起我们的注意。手术切除后大体检查诊断为III期腺癌(T4N1M0),伴有淋巴结受累。
根据监测、流行病学和最终结果(SEER)数据库的分析,发生小肠或大肠腺癌的患者发生第二次肠道癌症的风险增加。辅助治疗在接受根治性切除的患者中的作用尚不清楚。最近的回顾性和前瞻性研究有助于明确晚期小肠腺癌的最佳化疗方法。
通过我们的工作,我们展示了我们个人关于结直肠癌切除术后异时性小肠原发性癌的病例,并对文献进行了回顾。